• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Taris taps new CEO

July 19, 2010 By drugdelivery

Taris logo

Taris Biomedical hired Sarma Duddu to be its new president and CEO.

The Lexington, Mass.-based durg/device developer said Duddu brings 15 years of pharmaceutical industry experience to the corner office, where he’ll start immediately.

Duddu’s resumé includes stints as general manager and vice president of worldwide drug delivery technologies for Cephalon Inc. (NSDQ:CEPH) subsidiary CIMA Labs Inc and VP of pharmaceutical development at Nektar Therapeutics (NSDQ:NKTR), according to a press release. He also put in tome at SmithKline Beecham Pharmaceuticals.

Taris, launched in June 2009 with a $15 million financing round, is developing a drug/device combination designed to treat bladder conditions with lidocaine. The product “enables local sustained delivery of drug directly to the target tissue” to treat diseases including interstitial cystitis, painful bladder syndrome, bladder cancer, overactive bladder, urinary tract infections and chronic pelvic pain syndrome.

In November 2009 the company named Julie Lekstrom Himes to be its chief medical officer and lead its clinical development program. A month later Taris announced the completion of a Phase I study of its device, but declined to release any details of the study pending scientific publication. At the time, Taris COO and co-founder Christine Bunt said the study establishes proof-of-concept and sets the stage for a Phase II trial of the device this year.

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Taris Biomedical

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS